Glatiramer acetate as a clinically and cost-effective treatment of relapsing multiple sclerosis over 10 years of use within the National Health Service: Final results from the UK Risk Sharing Scheme-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Glatiramer acetate as a clinically and cost-effective treatment of relapsing multiple sclerosis over 10 years of use within the National Health Service: Final results from the UK Risk Sharing Scheme

Published:2019-10 Issue:4 Volume:5 Page:205521731989310
ISSN:2055-2173
Container-title:Multiple Sclerosis Journal - Experimental, Translational and Clinical
language:en
Short-container-title:Multiple Sclerosis Journal - Experimental, Translational and Clinical

Author:

Giovannoni G¹²,Brex PA³,Dhiraj D⁴,Fullarton J⁵,Freddi M⁵,Rodgers-Gray B⁵^ORCID,Schmierer K¹²^ORCID

Affiliation:

1. Blizard Institute, Barts, and The London School of Medicine and Dentistry, Queen Mary University London, UK

2. Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, UK

3. King's College Hospital NHS Foundation Trust, UK

4. Teva UK Limited, UK

5. Strategen Limited, UK

Publisher

SAGE Publications

Subject

Cellular and Molecular Neuroscience,Neurology (clinical)

Link

http://journals.sagepub.com/doi/pdf/10.1177/2055217319893103

Reference24 articles.

1. Burden of a Multiple Sclerosis Relapse

2. How People with Multiple Sclerosis Rate Their Quality of Life: An EQ-5D Survey via the UK MS Register

3. Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease.

4. Epidemiology of multiple sclerosis: results from a large observational study in the UK

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness Analysis of Multiple Sclerosis Treatment Approaches;IFMBE Proceedings;2024

2. Cost-Effectiveness of Multiple Sclerosis Therapies – A Literature Review;Acta Medica Bulgarica;2022-12-01

3. Cost associated with a relapse-free patient in multiple sclerosis: A real-world health indicator;PLOS ONE;2022-04-29

4. How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review;Neurology and Therapy;2021-07-19

5. Incorporating patients’ preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review;Expert Review of Pharmacoeconomics & Outcomes Research;2021-02-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3